Springer

Dear Author

Here are the proofs of your article.

- You can submit your corrections **online** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Together with the proof please return the cover sheet (including the *Copyright Transfer Statement)* and the *Offprint Order Form.* They can either be scanned and sent electronically or sent by fax.
- Remember to note the journal title, article number, and your name when sending your response via e-mail, fax or regular mail.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style.
  Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.

Please note

Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

`http://dx.doi.org/10.1007/s12031-014-0249-z`

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to: http://www.link.springer.com.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

The **printed version** will follow in a forthcoming issue.

Metadata of the article that will be visualized in OnlineFirst

1	Article Title	**Molecular Mechanisms Underlying the Nephroprotective Effects of PACAP in Diabetes**	
2	Article Sub- Title		
3	Article Copyright - Year	**Springer Science+Business Media New York 2014 (This will be the copyright line in the final PDF)**	
4	Journal Name	Journal of Molecular Neuroscience	
5	Corresponding Author	Family Name	**Reglodi**
6		Particle	
7		Given Name	**Dora**
8		Suffix	
9		Organization	University of Pécs
10		Division	Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team
11		Address	Szigeti u 12, Pécs 7624, Hungary
12		e-mail	dora.reglodi@aok.pte.hu
13	Author	Family Name	**Banki**
14		Particle	
15		Given Name	**Eszter**
16		Suffix	
17		Organization	University of Pécs
18		Division	Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team
19		Address	Szigeti u 12, Pécs 7624, Hungary
20		e-mail	
21	Author	Family Name	**Kovacs**
22		Particle	
23		Given Name	**Krisztina**
24		Suffix	
25		Organization	University of Pécs
26		Division	Department of Biochemistry and Medical Chemistry
27		Address	Pécs, Hungary
28		e-mail	

29		Family Name	**Nagy**
30		Particle	
31		Given Name	**Daniel**
32		Suffix	
33		Organization	University of Pécs
34	Author	Division	Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team
35		Address	Szigeti u 12, Pécs 7624, Hungary
36		Organization	University of Pécs
37		Division	Department of Pharmacology and Pharmacotherapy
38		Address	Pécs, Hungary
39		e-mail	
40		Family Name	**Juhasz**
41		Particle	
42		Given Name	**Tamas**
43		Suffix	
44	Author	Organization	University of Debrecen
45		Division	Department of Anatomy, Histology and Embryology, Medical and Health Science Center
46		Address	Debrecen, Hungary
47		e-mail	
48		Family Name	**Degrell**
49		Particle	
50		Given Name	**Peter**
51	Author	Suffix	
52		Organization	University of Pécs
53		Division	Internal Medicine 2/ Nephrology Center
54		Address	Pécs, Hungary
55		e-mail	
56		Family Name	**Csanaky**
57		Particle	
58		Given Name	**Katalin**
59	Author	Suffix	
60		Organization	University of Pécs
61		Division	Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team
62		Address	Szigeti u 12, Pécs 7624, Hungary

63		e-mail	
64	Author	Family Name	**Kiss**
65		Particle	
66		Given Name	**Peter**
67		Suffix	
68		Organization	University of Pécs
69		Division	Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team
70		Address	Szigeti u 12, Pécs 7624, Hungary
71		e-mail	
72	Author	Family Name	**Jancso**
73		Particle	
74		Given Name	**Gabor**
75		Suffix	
76		Organization	University of Pécs
77		Division	Surgical Research and Techniques
78		Address	Pécs, Hungary
79		e-mail	
80	Author	Family Name	**Toth**
81		Particle	
82		Given Name	**Gabor**
83		Suffix	
84		Organization	University of Szeged
85		Division	Department of Medical Chemistry
86		Address	Szeged, Hungary
87		e-mail	
88	Author	Family Name	**Tamas**
89		Particle	
90		Given Name	**Andrea**
91		Suffix	
92		Organization	University of Pécs
93		Division	Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team
94		Address	Szigeti u 12, Pécs 7624, Hungary
95		e-mail	
96	Schedule	Received	15 November 2013
97		Revised	
98		Accepted	22 January 2014

99	Abstract	Diabetic nephropathy is the leading cause of end-stage renal failure and accounts for 30–40 % of patients entering renal transplant programmes. The nephroprotective effects of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP38) against diabetes have been shown previously, but the molecular mechanisms responsible for these effects remain unknown. In the present study, we showed that PACAP treatment counteracted the diabetes-induced increase in the level of the proapoptotic pp38MAPK and cleaved caspase-3 and also decreased the p60 subunit of NFκB. The examined antiapoptotic factors, including pAkt and pERK1/2, showed a slight increase in the diabetic kidneys, while PACAP treatment resulted in a notable elevation of these proteins. PCR and Western blot revealed the downregulation of fibrotic markers, like collagen IV and TGF-β1 in the kidney. PACAP treatment resulted in increased expression of the antioxidant glutathione. We conclude that the nephroprotective effect of PACAP in diabetes is, at least partly, due to its antiapoptotic, antifibrotic and antioxidative effect in addition to the previously described antiinflammatory effect.
100	Keywords separated by ' - '	PACAP - Diabetes - Kidney - Oxidative stress - Apoptosis
101	Foot note information	

J Mol Neurosci
DOI 10.1007/s12031-014-0249-z

Molecular Mechanisms Underlying the Nephroprotective Effects of PACAP in Diabetes

Eszter Banki · Krisztina Kovacs · Daniel Nagy · Tamas Juhasz · Peter Degrell · Katalin Csanaky · Peter Kiss · Gabor Jancso · Gabor Toth · Andrea Tamas · Dora Reglodi

Received: 15 November 2013 / Accepted: 22 January 2014

Abstract Diabetic nephropathy is the leading cause of end-stage renal failure and accounts for 30–40 % of patients entering renal transplant programmes. The nephroprotective effects of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP38) against diabetes have been shown previously, but the molecular mechanisms responsible for these effects remain unknown. In the present study, we showed that PACAP treatment counteracted the diabetes-induced increase in the level of the proapoptotic pp38MAPK and cleaved caspase-3 and also decreased the p60 subunit of NFκB. The examined antiapoptotic factors, including pAkt and pERK1/2, showed a slight increase in the diabetic kidneys, while PACAP treatment resulted in a notable elevation of these proteins. PCR and Western blot revealed the downregulation of fibrotic markers, like collagen IV and TGF-β1 in the kidney. PACAP treatment resulted in increased expression of the antioxidant glutathione. We conclude that the nephroprotective effect of PACAP in diabetes is, at least partly, due to its antiapoptotic, antifibrotic and antioxidative effect in addition to the previously described antiinflammatory effect.

Keywords PACAP · Diabetes · Kidney · Oxidative stress · Apoptosis

E. Banki · D. Nagy · K. Csanaky · P. Kiss · A. Tamas · D. Reglodi (✉)
Department of Anatomy, PTE-MTA "Lendulet" PACAP Research Team, University of Pécs, 7624 PécsSzigeti u 12, Hungary
e-mail: dora.reglodi@aok.pte.hu

K. Kovacs
Department of Biochemistry and Medical Chemistry, University of Pécs, Pécs, Hungary

D. Nagy
Department of Pharmacology and Pharmacotherapy, University of Pécs, Pécs, Hungary

T. Juhasz
Department of Anatomy, Histology and Embryology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary

P. Degrell
Internal Medicine 2/ Nephrology Center, University of Pécs, Pécs, Hungary

G. Jancso
Surgical Research and Techniques, University of Pécs, Pécs, Hungary

G. Toth
Department of Medical Chemistry, University of Szeged, Szeged, Hungary

Introduction

In the present study, we aimed at investigating the nephroprotective mechanisms of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) in an experimental diabetic nephropathy. Diabetic nephropathy (DN) is a common microvascular complication of diabetes. The development as well as the progression of the disease is multifactorial due to its profound genetic background besides the well-known environmental impacts, explaining why 30–40 % of all diabetic patients suffer from this diabetic complication (Klein et al. 1984). Glucose uptake is insulin independent in neuronal, retinal, glomerular and endothelial cells, leading to excessive glucose uptake in extracellular hyperglycemia (Di Mario and Pugliese 2001). Although a few decades ago diabetic nephropathy was considered a primarily glomerular disease, nowadays increasing emphasis is put on the tubulointerstitial alterations. Indeed, the stage of tubulointerstitial injury is considered to be a reliable prognostic factor in progressive kidney diseases, including diabetic nephropathy (Nath 1998). Key factors that are involved in diabetic kidney damage are as follows: (1) oxidative stress, (2) overproduction of advanced glycation end products (AGE), (3)

apoptosis, (4) excessive production of prosclerotic growth factors and (5) inflammation due to the overproduction of proinflammatory cytokines (Gnudi 2012; Sun et al. 2013). Since the neuropeptide PACAP is known to exert antiinflammatory, antiapoptotic and antioxidant effects, it seems to be a suitable candidate to prevent the development or delay the progression of DN.

PACAP is a member of the vasoactive intestinal polypeptide (VIP)/secretin/glucagon family and exists in two biologically active forms, PACAP1-27 and PACAP1-38. PACAP38 has been shown to have more prolonged effects compared to PACAP27 in most studies (Araki and Takagi 1992; Lindén et al. 1999). PACAP acts via G-protein-coupled receptors: PAC1, specific for PACAP, and VPAC1 and VPAC2 which also bind VIP with the same affinity.

In addition to its very first known effect, namely adenylate cyclase activation in the hypophysis, PACAP exerts numerous effects in the endocrine, respiratory, gastrointestinal and urogenital systems (Miyata et al. 1989; Girard et al. 2012; Koppan et al. 2012; Moody et al. 2012; Nedvig et al. 2012; Syed et al. 2012; Wada et al. 2013). Moreover, the neuropeptide has been shown to be involved in neuroprotection and general cytoprotection. PACAP is also involved in the regulation of carbohydrate metabolism, although its exact role seems to be complex. Its ability to protect β cells and enhance insulin secretion glucose-dependently has been shown in several studies (Sakurai et al. 2011). Recently, PACAP has been proven to upregulate selenoprotein T in pancreatic β cells, leading to increased insulin secretion (Prevost et al. 2013). However, PACAP also effectively stimulates the release of adrenalin and glucagon. As a result, publications seem to be rather contradictory in the effect of PACAP treatment on blood glucose levels (Sekiguchi et al. 1994; Filipsson et al. 1998; Yada et al. 2000).

PACAP exerts renoprotective effects against several nephrotoxic agents, like hydrogen peroxide-induced oxidative stress in vitro and in vivo or ischemia/reperfusion injury (Szakaly et al. 2008; Horvath et al. 2011; Khan et al. 2012; Reglodi et al. 2012). PACAP has also been shown to attenuate kidney injuries induced by multiple myeloma, cyclosporine A, gentamicin and short-term diabetes (Arimura et al. 2006; Li et al. 2007, 2008). Recently, we have provided evidence for similar protection against 8-week diabetes-induced kidney damage (Banki et al. 2013).

The protective effects of PACAP are mediated through its antiinflammatory, antiapoptotic and antioxidative effects. The antiinflammatory effects involve the inhibition of proinflammatory cytokine (i.e. tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) production and NFκB activation through PAC1- and VPAC1 receptor-mediated signaling (Arimura et al. 2006). We have already proven the importance of the antiinflammatory effect in long-term diabetic nephropathy, resulting in marked downregulation of several cytokines, like cytokine-induced neutrophil chemokine (CINC-1), tissue inhibitor of metalloproteinase 1 (TIMP-1), lipopolysaccharide-induced CXC chemokine (LIX) and monokine induced by gamma interferon (MIG) (Banki et al. 2013). However, the further mechanisms leading to the significant nephroprotective effect in diabetic nephropathy remain unknown.

Materials and Methods

Animals

Adult male Wistar rats (n=33) weighing 250–300 g were housed under light/dark cycles of 12:12 h and received normal rat chow and drinking water ad libitum. Rats were randomly divided into four groups: (1) untreated control (n=10); (2) PACAP-treated control (n=6); (3) untreated diabetic (n=7); and (4) PACAP-treated diabetic (n=10). Control animals received saline i.v., while diabetic groups were administered 65 mg/kg streptozotocin (Sigma, Hungary) i.v. PACAP-treated animals were given 20 μg PACAP1-38 i.p. every second day, starting simultaneously with the streptozotocin injection.

Animals were considered diabetic in cases where they showed elevated blood glucose levels (>11 mmol/l) measured by a blood glucose monitor (Accu-Check Active, Roche, Hungary). After 8 weeks of survival, animals were sacrificed with an overdose of anaesthetics and the kidneys were removed. For RT-PCR and Western blot, kidney samples were taken from the cortex of the kidney close to the superior pole. Experimental procedures were carried out in accordance with approved protocols (University of Pécs; BA02/2000-15024/2011).

RT-PCR Analysis

Tissue samples were dissolved in Trizol (Applied Biosystems, Foster City, CA, USA) for 30 min and mechanically homogenized. After the addition of 20 % RNase-free chloroform, samples were centrifuged at 4 °C at 10,000×g for 15 min. Samples were incubated in 500 μL of RNase-free isopropanol at −20 °C for 1 h and then total RNA was harvested in RNase-free water and stored at −20 °C. The assay mixture for reverse transcriptase reaction contained 2 μg RNA, 0.112 μM oligo(dT), 0.5 mM dNTP, 200 U of High Capacity RT (Applied Bio-Systems) in 1× RT buffer. Primers used in the RT-PCR analysis of collagen IV all isotype were as follows: Col4a1: 5′-TCG GCT ATT CCT TCG TGA TG-3′ and 5′-GGA TGG CGT GGG CTT CTT-3′ (GenBank ID: NM_009931.2, 52 °C, amplimer size 209 bp); and for actin—Actb: 5′-GCC AAC CGT GAA AAG ATG A-3′ and 5′-CAA GAA GGA AGG CTG GAA AA-3′ (GenBank ID:

NM_007393, amplimer size 462 bp). Amplifications were performed in a thermal cycler (Labnet MultiGene™ 96-well Gradient Thermal Cycler; Labnet International, Edison, NJ, USA) in a final volume of 25 μL (containing 1 μL forward and reverse primers [0.4 μM], 0.5 μL dNTP [200 μM] and 5 U of Promega GoTaq® DNA polymerase in 1× reaction buffer) as follows: 95 °C, 2 min, followed by 35 cycles (denaturation, 94 °C, 1 min; annealing at 52 °C for Col4a1 or 53 °C for Actb for 1 min; extension, 72 °C, 90 s) and then 72 °C, 10 min. PCR products were analysed by electrophoresis in 1.2 % agarose gel containing ethidium bromide. Actin was used as the internal control. Optical density of signals was measured by using ImageJ 1.40 g freeware and results were normalised to actin.

Western Blot

The specimens were put into 100 μL of ice-cold homogenization buffer containing 50 mM Tris–HCl buffer (pH 7.0), 10 μg/mL Gordox, 10 μg/mL leupeptine, 1 mM phenylmethylsulphonyl-fluoride (PMSF), 5 mM benzamidine and 10 μg/mL trypsin inhibitor as protease inhibitors. Samples were stored at −70 °C. Tissue samples were sonicated by pulsing burst for 30 s at 40 A (Cole-Parmer, IL, USA). Samples for SDS-PAGE were prepared by the addition of fivefold concentrated electrophoresis sample buffer (20 mM Tris–HCl pH 7.4, 0.01 % bromophenol blue dissolved in 10 % SDS, 100 mM β-mercaptoethanol) to kidney homogenates to set equal protein concentration of samples and boiled for 10 min. About 40 μg of protein was separated by 7.5 % SDS-PAGE gel for detection of tAkt, pAkt, pERK1/2, p38MAPK, pp38MAPK, cleaved caspase-3, TGF-β1, collagen type IV, β-actin and NFκB. Proteins were transferred electrophoretically to nitrocellulose membranes. After blocking with 5 % non-fat dry milk in phosphate-buffered saline with 0.1 % Tween 20 (PBST), membranes were washed and exposed to the following primary antibodies overnight at 4 °C: monoclonal anti-Akt, monoclonal phospho-specific anti-Akt-1 Ser473, monoclonal phospho-specific anti-ERK1/2 Thr202/Tyr204, monoclonal anti-p38 MAPK, monoclonal phospho-specific anti-p38 MAPK (1:500; Cell Signaling Technology, USA), monoclonal anti-NFκB, monoclonal anti-caspase-3 (1:500; Santa Cruz, USA), polyclonal anti-TGF-β1 antibody (1:400; Abcam, Cambridge, UK), monoclonal anti-collagen type IV antibody (1:400; Chemicon/Millipore, USA) and monoclonal anti-actin antibody (1:10,000; Sigma, Hungary) were used. After washing for 40 min in PBST, membranes were incubated with anti-mouse IgG (1:1500; Bio-Rad Laboratories, USA) or anti-rabbit IgG (1:3,000; Bio-Rad Laboratories, USA). Signals were detected by enhanced chemiluminescence (Millipore, USA) according to the instructions of the manufacturer. Actin was used as the internal control. Optical density of Western blot signals was measured by using ImageJ 1.40 g freeware and the results were normalised to actin.

Biochemical Assay of Oxidative Stress Markers

Malondialdehyde (MDA) was measured as previously described (Placer et al. 1966). Briefly, MDA was measured in kidney homogenates with the addition of TBA (saturated thiobarbituric acid in 10 % perchloric acid)-TCA (20 % trichloroacetic acid) reagent. After incubation at 100 °C for 20 min, samples were placed in ice-cold water and were centrifuged for 15 min at 4,000 rpm. MDA concentration was determined spectrophotometrically by measuring the absorbance at 532 nm against TBA+TCA reagent. From the concentration vs. extinction curve, the MDA value of the tissue sample could be calculated in micromole per gram tissue weight.

Reduced glutathione (GSH) was quantified as described by Sedlak and Lindsay (1968). After adding 10 % TCA, kidney homogenates were centrifuged for 15 min at 4,000 rpm. TRIS-buffer was added to the supernatant and samples were measured at 412 nm after adding DTNB to the mixture. Values of glutathione were expressed in micromole per gram tissue weight.

Kidney homogenates were centrifuged for 20 min at 16,000 rpm, and the supernatant was used to measure the concentration of superoxide dismutase (SOD) as described previously (Misra and Firdovich 1972). SOD inhibited the transformation of adrenaline to adrenochrome, which absorbed maximally at 480 nm. Quantification of SOD is based on the degree of inhibition. The value of SOD was given in international units per gram tissue weight.

Electron Microscopy

Kidney samples were cut into maximum 1 mm^3 pieces and were fixed in 5 % glutaraldehyde. Post-fixation was performed with 1 % osmium tetroxide. After dehydration in ascending alcohol and subsequent transfer to propylene oxide, samples were embedded in Araldite resin. Semithin sections were cut by a ultramicrotome (Leica Ultracut R) and stained by toluidine blue. Ultrathin sections were prepared from the area of interest and were contrasted by uranyl-acetic acid and lead citrate. Slides were eventually examined using JEOL 1200 EX-II electron microscope.

Statistical Analysis

Statistical analysis was performed by Microsoft Office Excel and GraphPad software. Analysis of variance (ANOVA) with Bonferroni correction was used to detect significant differences between groups. p value less than 0.05 was considered to be statistically significant.

Results

RT-PCR analysis revealed marked elevation in the collagen IV mRNA, a collagen uniquely present in the basement membrane. PACAP treatment successfully counteracted this increase (Fig. 1). We then measured the protein expression of two key factors involved in the fibrotic processes of diabetic nephropathy, namely collagen IV and TGF-β1. Diabetes resulted in excessive expression of collagen IV and TGF-β1, which was attenuated by PACAP38, reaching the level of normal kidneys in the case of collagen IV (Figs. 2 and 3a, b).

Next we investigated the levels of anti- and proapoptotic proteins by Western blot. PACAP alone caused increased expression of the phosphorylated form of Akt. Diabetic nephropathy is accompanied by excessive apoptosis, shown by the upregulation of the phosphorylated forms of the proapoptotic pp38MAPK. However, the antiapoptotic Akt and ERK1/2 were also activated. PACAP treatment in diabetic animals led to a remarkable increase in the activation of the antiapoptotic factors, like pAkt and pERK1/2, and decreased the level of pp38MAPK. PACAP treatment was effective in decreasing the elevated cleaved caspase-3 levels observed in diabetic animals. We then aimed at measuring the level of p60 NFκB, a protein known to control both cytokine production and cell survival. We found that p60 NFκB was upregulated in the diabetic samples. PACAP treatment in diabetic kidneys resulted in a remarkable decrease in the p60 subunit of NFκB (Figs. 2 and 3c–h).

Biochemical assay of the oxidative stress markers revealed a significant elevation in the kidney GSH concentration of the PACAP-treated diabetic group compared to the untreated diabetic one. No changes were observed in the kidney SOD or MDA concentration of the diabetic groups compared to that of the intact animals; however, PACAP caused a significant increase in the SOD level of the control animals (Fig. 4).

Electron microscopy revealed segmental thickening of the glomerular basement membrane (GBM) in several parts of the untreated diabetic glomeruli. The thickness of these parts of the GBM was significantly greater than the GBM in control,



Q2 **Fig. 1** mRNA expression pattern of collagen type IV in control, PACAP-treated control, diabetic and PACAP-treated diabetic kidneys. For RT-PCR reactions, actin was used as the control. ***$p<0.001$ vs. control; ###$p<0.001$ vs. control + PACAP; &&&$p<0.001$ vs. diabetes



Fig. 2 Western blots of collagen type IV, TGF-β1, pERK1/2, pAkt, pp38MAPK, cleaved caspase-3 and p60 NFκB in untreated or PACAP-treated control and diabetic animal groups. For Western blot analysis, β-actin was used as a control

PACAP-treated control and PACAP-treated diabetic kidneys. However, we could not detect any changes between the non-thickened part of the GBM in diabetic animals and the thickness of the GBM in the control. Most importantly, PACAP-treated diabetic animals did not show this focal segmental thickening; there was no difference between PACAP-treated or untreated control and PACAP-treated diabetic animals. Podocytes in the PACAP-treated diabetic kidneys did not show any morphological alterations compared to the control groups, although severe podocyte injury was present in the diabetic glomeruli with marked foot process broadening and extensive flattening (Fig. 5).

Discussion

In the present study, we demonstrated that in vivo PACAP treatment exhibits protective effect through inhibiting apoptotic, fibrotic and oxidative pathways, key mediators in the development and progression of diabetic nephropathy and preventing diabetes-induced podocyte injury in 8-week diabetes. The present experiment was based on our previous finding, showing that PACAP38 effectively counteracted the



Fig. 3 Effect of 8-week PACAP treatment and diabetes on the protein expression of collagen type IV (**a**), TGF-β1 (**b**), pERK1 (**c**), pERK2 (**d**), pAkt (**e**), pp38MAPK (**f**), cleaved caspase-3 (**g**) and p60 NFκB (**h**). *$p<0.05$; **$p<0.01$; ***$p<0.001$ vs. control; $^{\#}p<0.05$; $^{\#\#\#}p<0.01$; $^{\#\#\#}p<0.001$ vs. control+PACAP; &$p<0.05$; &&$p<0.01$; &&&$p<0.001$ vs. diabetes

histological alterations of 8-week diabetic nephropathy. Decreased PAS-positive area expansion, glycogen deposits in tubular epithelial cells and significantly diminished vascular hyalinosis proved the ameliorative effect of PACAP. Moreover, we provided evidence that this effect is at least partially mediated through its antiinflammatory effect (Banki et al. 2013).

As we mentioned earlier, the effect of exogenous PACAP on glucose homeostasis is not fully elucidated. However, the pivotal role of endogenous PACAP on regulating blood sugar level seems to be more evident. Chronic administration of the antagonist PACAP6-27 was found to deteriorate insulin sensitivity and glucose tolerance in mice (Green et al. 2006). Newborn PACAP knockout mice showed decreased glucose and intrahepatic glucagon levels, but significantly higher insulin levels compared to the control PACAP$^{+/+}$ mice (Gray et al. 2001). Although PACAP protects pancreatic β cells against streptozotocin-induced apoptosis, under our experimental circumstances, we could not find significant changes between the blood sugar levels of the PACAP-treated and untreated diabetic rats after 8 weeks of survival, meaning that this factor cannot be responsible for the ameliorative effect in diabetic nephropathy (Onoue et al. 2008; Banki et al. 2013).

In the present study, we found that diabetes resulted in upregulated NFκB levels compared to the controls, while PACAP treatment effectively diminished the renal NFκB expression. Several previous studies revealed that PACAP, which is structurally similar to the related VIP peptide, prevents NFκB translocation to the nucleus via inhibition of IκB phosphorylation both in vitro and in vivo (Leceta et al. 2000; Delgado and



Fig. 4 Changes in renal expression of glutathione (GSH; **a**), superoxide dismutase (SOD; **b**) and malondialdehyde (MDA; **c**). Values are given as mean micromoles per gram, international units per gram and micromoles per gram ± SEM, respectively. *$p<0.05$ vs. diabetes + PACAP; $^{\#}p<0.05$ vs. control

Ganea 2001; Delgado et al. 2002; Ganea and Delgado 2003). Antioxidants and inhibitors of the renin-angiotensin-aldosterone system, which exert their nephroprotective effect partially through controlling the action of NFκB, are extensively used in the treatment of diabetic nephropathy (Liu et al. 2009). In diabetic nephropathy, NFκB can be activated by mesangial cells, hyperglycemia-induced ROS production, renin-angiotensin-aldosterone system (RAAS) activation, TGF-β1, TNFα and interleukins (Iwamoto et al. 2005; Gnudi 2012). NFκB plays an important role in several renal diseases, such as nephritis, proteinura and tubulointerstitial disorders, and it is the key transcriptional regulator of diabetic kidney disease (Sakurai et al. 1996; Iwamoto et al. 2005). It activates the transcription of a variety of factors involved in cell proliferation and inflammation contributing to the progression of diabetic nephropathy (Navarro-González et al. 2011). Mesangial cell proliferation, tubular cell damage and excessive secretion of proinflammatory cytokines, chemokines and adhesion molecules occur as a result of NFκB activation (Mezzano et al. 2004; Chen et al. 2008).

Activation of NFκB under diabetic conditions is assumed to mediate ROS-induced apoptotic changes (Aoki et al. 2011). Extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen activated protein kinase (MAPK) and Jun kinase-mediated pathways are stimulated upon NFκB activation. In this study, we showed that PACAP increased the expression of antiapoptotic factors, like pAkt and pERK1/2, while down-regulated the proapoptotic pp38MAPK. The markedly increased expression of the antiapoptotic proteins in untreated diabetic animals may result from the induction of the protective compensatory mechanisms. The antiapoptotic effect of PACAP was associated with decreased cleaved caspase-3. Caspase-3, as an effector caspase, plays a critical role in receptor-mediated, mitochondria-dependent and endoplasmic reticulum stress-induced apoptotic mechanisms, which are involved in hyperglycemia-induced podocyte loss (Susztak et al. 2006; Tunçdemir and Oztürk 2011; Gui et al. 2012). Apoptosis is a rare event in the normal kidney; however, it is present in human diabetic kidney biopsies, similar to other kidney disorders. Not only proximal and distal tubular cells but also endothelial and mesangial cells are affected by apoptosis in diabetes (Woo 1995; Kumar et al. 2004).

Similar to the pathomechanism of the tubulointerstitial injury in myeloma kidney, tubular epithelial cells start to produce excessive amount of proinflammatory cytokines in diabetic nephropathy as well. TGF-β1 is a prosclerotic cytokine produced by mesangial and proximal tubular cells (Gilbert et al. 1998). It is the key mediator of hyperglycemia-induced changes in the kidney, accelerating the production of extracellular matrix in excess through epithelial-to-mesenchymal cell transformation (di Paolo et al. 1996; Hills Paul and Squires 2010). The accumulation of fibronectin, collagen IV and laminin is caused by simultaneous overproduction and decreased breakdown of proteins in mesangial matrix, glomerular and tubular basal membrane and interstitium, resulting in a severely damaged renal morphology and function (Mauer et al. 1984; Steffes et al. 1989). Similar to our results in rat kidney, PACAP was found to significantly lower the TGF-β1 production in stimulated macrophages (Sun et al. 2000). Li et al. reported that PACAP provided a protective effect against early diabetic nephropathy. They found that this effect is mediated via inhibiting TGF-β1 and TNFα pathways, resulting in remarkably attenuated histological changes in the PACAP-treated animals. Similar to Li et al., in the present study, we showed decreased TGF-β1 and collagen IV levels in the PACAP-treated diabetic compared to the untreated diabetic kidneys (Li et al. 2008). Therefore, these findings provide explanation for the suppressed extracellular matrix expansion observed in the histological sections of PACAP-treated animals. Antioxidants and AGE inhibitors,



Fig. 5 Representative electron microscopic images of diabetic (**a**) and PACAP-treated diabetic kidneys (**b**). Focal segmental thickening of the glomerular basement membrane (GBM) (*paired arrows*) was observed in the diabetic kidney, while other parts of the GBM remained unchanged (*paired arrowheads*). Fusion of the foot processes of the podocytes (*encircled*) was also remarkable. PACAP treatment effectively counteracted the diabetes-induced GBM thickening and podocyte injury (**b**). *Scale bar*= 2 μm. *Inserts* show *enlarged encircled parts* of pictures **a** and **b** to visualize the severe injury of the podocyte foot processes (fused foot processes marked by *asterisks*, **c**), while PACAP treatment resulted in intact podocyte foot processes (foot processes marked by *asterisks*, **d**). Thickness of GBM (**e**). Basement membrane thickness measurements were performed in the entire basement membrane in control, control + PACAP and in diabetes + PACAP-treated groups. Data are given separately for segmental thickenings in diabetic animals (*bar*: diabetes segmental) and for areas showing no segmental thickening (*bar*: diabetes nonsegmental). Data show mean ± SEM. ***$p<0.001$ vs. all other groups

which are already commonly used in clinical practice, also effectively reduce TGF-β1, fibronectin and collagen IV levels (Ha et al. 1999; Kelly et al. 2001). The results of anti-TGF-β1 treatments are promising; therefore, any candidate, which downregulates the TGF-β1 pathway, could be effective in the treatment of diabetic nephropathy (Sharma et al. 1996; Ziyadeh et al. 2000).

The importance of oxidative stress in the development of diabetes and diabetic complications is well known (Usuki et al. 2011). The diabetogenic effect of streptozotocin in pancreatic β cells also involves the overproduction of nitric oxide (NO) and superoxide (O_2^-) (Nukatsuka et al. 1988; Kaneto et al. 1995). The mitochondrial free radicals were shown to stimulate the polyol-PKC, hexosamine and AGE pathways, contributing to the progression of DN. The vital role of glutathione is based on its ability to neutralize electrophils produced by metabolic processes or external stimuli in order to prevent the organism against their harmful effects. Conditions associated with high levels of free radicals, like diabetes, probably inactivate the mitochondrial GSH carriers, resulting in depressed antioxidant mechanisms. Non-enzymatic glycation of renal mitochondrial proteins was shown to be at least partially responsible for these changes (Lash 2006). Moreover, increased activity of NADPH oxidase results in severely lowered NADPH levels, leading to impaired glutathione recovery. Therefore, not only the increased oxidative stress but also the inactivated defence mechanisms contribute to the oxidative damage of the renal cells, leading to more severe consequences of the oxidative agents (Stanton 2011; Gnudi 2012). Changes in the concentration and redox status of GSH lead to mitochondrial DNA damage and induction of apoptotic pathways (Marchetti et al. 1997; Davis et al. 2001). We found that PACAP is capable of normalising the decreased GSH levels in the diabetic kidney, suggesting an antioxidative effect of PACAP. This finding is similar to our previous studies, where PACAP was found to exert antioxidative effects in oxidative stress-induced renal and hepatic cell damage, intestinal cold preservation and warm ischemic injury (Ferencz et al. 2010a, 2010b; Horvath et al. 2011). Usually diabetes is also associated with decreased superoxide dismutase (SOD) and elevated malondialdehyde (MDA) levels; however, under our experimental circumstances, we could not detect diabetes-induced changes in these factors.

Based on these data, PACAP seems to be a promising candidate in treating diabetic nephropathy. Similar to other

studies showing that PACAP is a strong cytoprotective agent, we have also provided evidence that PACAP is highly effective in diabetic nephropathy. This efficacy is most probably due to PACAP acting at several levels and directly and/or indirectly (via antiinflammatory, antiapoptotic and antioxidant mechanisms) affecting more cell types in the kidney. However, several aspects have to be examined before the clinical application of PACAP. In rats, no side effects were observed after systemic administration of PACAP. Indeed, even a human study proved that systemic infusion of the peptide causes no changes in the physiological parameters apart from transient flushing (Li et al. 2007). The other drawback of systemic PACAP administration is the poor bioavailability, since the half life of the peptide in the circulation is only 5–10 min due to its rapid degradation by dipeptidyl peptidase IV (DPPIV) (Banks et al. 1993; Bourgault et al. 2008). However, nowadays, several studies aim at finding an easy and reliable way of PACAP treatment (Onoue et al. 2011).

In summary, our present study demonstrated the molecular mechanisms involved in the protective effect of PACAP. Besides the contribution of the previously proven antiinflammatory effect, antiapoptotic, antioxidative and antifibrotic mechanisms are responsible for the protective effect of PACAP in 8-week diabetic nephropathy in rats.

Acknowledgments This study was supported by OTKA K104984, 108596, PD109644, TAMOP 4.2.2.A-11/1/KONV-2012-0024, Arimura Foundation and PTE-MTA "Lendület" Program. This research was realized in the frames of TAMOP 4.2.4. A/2-11-1-2012-0001 "National Excellence Program—Elaborating and operating an inland student and researcher personal support system convergence program", Bolyai Scholarship. The project was subsidized by the European Union and co-financed by the European Social Fund.

References

Aoki M, Nata T, Morishita R et al (2011) Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension 38: 48–55

Araki N, Takagi K (1992) Relaxant effect of pituitary adenylate cyclase-activating polypeptide on guinea-pig tracheal smooth muscle. Eur J Pharmacol 216:113–117

Arimura A, Li M, Batuman V (2006) Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107: 661–668

Banki E, Degrell P, Kiss P et al (2013) Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides 42:125–130

Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood–brain barrier. J Pharmacol Exp Ther 267:690–696

Bourgault S, Vaudry D, Botia B et al (2008) Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29:919–932

Chen L, Zhang J, Zhang Y, Wang Y, Wang B (2008) Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats. Inflamm Res 57:199–204

Davis W Jr, Ronai Z, Tew KD (2001) Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther 296:1–6

Delgado M, Ganea D (2001) Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch Physiol Biochem 109:377–382

Delgado M, Jonakait GM, Ganea D (2002) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 39:148–161

Di Mario U, Pugliese G (2001) 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia 44:674–692

Di Paolo S, Gesualdo L, Ranieri E, Grandaliano G, Schena FP (1996) High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. Am J Pathol 149:2095–2106

Ferencz A, Kiss P, Weber G et al (2010a) Comparison of intestinal warm ischemic injury in PACAP knockout and wild-type mice. J Mol Neurosci 42:435–442

Ferencz A, Weber G, Helyes Z, Hashimoto H, Baba A, Reglodi D (2010b) Presence of endogenous PACAP-38 ameliorated intestinal cold preservation tissue injury. J Mol Neurosci 42:428–434

Filipsson K, Pacini G, Scheurink AJ, Ahren B (1998) PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. Am J Physiol 274:834–842

Ganea D, Delgado M (2003) The neuropeptides VIP/PACAP and T cells: inhibitors or activators? Curr Pharm Des 9:997–1004

Gilbert RE, Cox A, Wu LL et al (1998) Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47:414–422

Girard BM, Tompkins JD, Parsons RL, May V, Vizzard MA (2012) Effects of CYP-induced cystitis on PACAP/VIP and receptor expression in micturition pathways and bladder function in mice with overexpression of NGF in urothelium. J Mol Neurosci 48:730–743

Gnudi L (2012) Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrol Dial Transplant 27:2642–2649

Gray SL, Cummings KJ, Jirik FR, Sherwood NM (2001) Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol 15:1739–1747

Gui D, Guo Y, Wang F et al (2012) Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS ONE 7:e39824

Ha H, Yu MR, Kim KH (1999) Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med 26:944–950

Hills Paul E, Squires PE (2010) TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 31:68–74

Horvath G, Brubel R, Kovacs K et al (2011) Effects of PACAP on oxidative stress-induced cell death in rat kidney and human hepatocyte cells. J Mol Neurosci 43:67–75

Iwamoto M, Mizuiri S, Arita M, Hemmi H (2005) Nuclear factor-κB activation in diabetic rat kidney: evidence for involvement of P-selectin in diabetic nephropathy. Tohoku J Exp Med 206:163–171

Kaneto H, Fujii J, Seo HG et al (1995) Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 44:733–738

Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME (2001) Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12:2098–2107

Khan AM, Li M, Abdulnour-Nakhoul S, Maderdrut JL, Simon EE, Batuman V (2012) Delayed administration of pituitary adenylate cyclase-activating polypeptide 38 ameliorates renal ischemia/reperfusion injury in mice by modulating Toll-like receptors. Peptides 38:395–403

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464–1474

Koppan M, Varnagy A, Reglodi D et al (2012) Correlation between oocyte number and follicular fluid concentration of pituitary adenylate cyclase-activating polypeptide (PACAP) in women after superovulation treatment. J Mol Neurosci 48:617–622

Kumar D, Robertson S, Burns KD (2004) Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 259:67–70

Lash LH (2006) Mitochondrial glutathione transport: physiological, pathological and toxicological implications. Chem Biol Interact 163:54–67

Leceta J, Gomariz RP, Martinez C et al (2000) Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci 921:92–102

Li M, Maderdrut JL, Lertora JJ, Batuman V (2007) Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28:1891–1895

Li M, Maderdrut JL, Lertora JJ, Arimura A, Batuman V (2008) Renoprotection by pituitary adenylate cyclase activating polypeptide in multiple myeloma and other kidney diseases. Regul Pept 145:24–32

Lindén A, Cardell LO, Yoshihara S, Nadel JA (1999) Bronchodilation by pituitary adenylate cyclase-activating peptide and related peptides. Eur Respir J 14:443–451

Liu XP, Pang YJ, Zhu WW et al (2009) Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin Exp Pharmacol Physiol 36:287–296

Marchetti P, Decaudin D, Macho A et al (1997) Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. Eur J Immunol 27:289–296

Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC (1984) Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143–1155

Mezzano S, Aros C, Droguett A et al (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19:2505–2512

Misra HP, Firdovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247:3170–3175

Miyata A, Arimura A, Dahl RR et al (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567–574

Moody TW, Di Florio A, Jensen RT (2012) PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells. J Mol Neurosci 48:660–666

Nath KA (1998) The tubulointerstitium in progressive renal disease. Kidney Int 54:992–994

Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7:327–340

Nedvig K, Weber G, Nemeth J et al (2012) Changes of PACAP immunoreactivities and cytokine levels after PACAP-38 containing intestinal preservation and autotransplantation. J Mol Neurosci 48:788–794

Nukatsuka M, Sakurai H, Yoshimura Y, Nishida M, Kawada J (1988) Enhancement by streptozotocin of O2– radical generation by the xanthine oxidase system of pancreatic beta-cells. FEBS Lett 239:295–298

Onoue S, Hanato J, Yamada S (2008) Pituitary adenylate cyclase activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression. FEBS J 275:5542–5551

Onoue S, Hanato J, Kuriyama K, Mizumoto T, Yamada S (2011) Development of PACAP38 analogue with improved stability: physicochemical and in vitro/in vivo pharmacological characterization. J Mol Neurosci 43:85–93

Placer ZA, Cushman LL, Johnson BC (1966) Estimation of product of lipid peroxidation (malondialdehyde) in biochemical systems. Anal Biochem 16:359–364

Prevost G, Arabo A, Jian L et al (2013) The PACAP-regulated gene Selenoprotein T is abundantly expressed in mouse and human β-cells and its targeted inactivation impairs glucose tolerance. Endocrinology 154:3796–3806

Reglodi D, Kiss P, Horvath G et al (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 46:61–70

Sakurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T (1996) Activation of transcription factor NF-kB in experimental glomerulonephritis in rats. Biochim Biophys Acta 1316:132–138

Sakurai Y, Shintani N, Hayata A, Hashimoto H, Baba A (2011) Trophic effects of PACAP on pancreatic islets: a mini-review. J Mol Neurosci 43:3–7

Sedlak J, Lindsay R (1968) Estimation of total protein-bound and nonprotein sulphydryl groups in tissue with Ellman's reagent. Anal Biochem 25:192–205

Sekiguchi Y, Kasai K, Hasegawa K, Suzuki Y, Shimoda S (1994) Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro. Life Sci 55:1219–1228

Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522–530

Stanton RC (2011) Oxidative stress and diabetic kidney disease. Curr Diab Rep 11:330–336 Q4

Steffes MW, Osterby R, Chavers B, Mauer SM (1989) Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38:1077–1081

Sun W, Tadmori I, Yang L, Delgado M, Ganea D (2000) Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages. J Neuroimmunol 107:88–99

Sun YM, Su Y, Li J, Wang LF (2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 433:359–361

Susztak K, Raff AC, Schiffer M, Böttinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–233

Syed AU, Koide M, Braas KM, May V, Wellman GC (2012) Pituitary adenylate cyclase-activating polypeptide (PACAP) potently dilates middle meningeal arteries: implications for migraine. J Mol Neurosci 48:574–583

Szakaly P, Kiss P, Lubics A et al (2008) Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion. J Mol Neurosci 36:89–96

Tunçdemir M, Oztürk M (2011) The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acta Histochem 113:826–832

Usuki S, Tsai YY, Morikawa K et al (2011) IGF-1 induction by acylated steryl β-glucosides found in a pre-germinated brown rice diet reduces oxidative stress in streptozotocin-induced diabetes. PLoS ONE 6: e28693

Wada Y, Nakamachi T, Endo K et al (2013) PACAP attenuates NMDA-induced retinal damage in association with modulation of the microglia/macrophage status into an acquired deactivation subtype. J Mol Neurosci 51:493–502

Woo D (1995) Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333:18–25

Yada T, Sakurada M, Filipsson K, Kikuchi M, Ahren B (2000) Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. Ann N Y Acad Sci 921:259–263

Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long term prevention of renal insufficiency, excess matrix gene expression and glomerular mesangial matrix expression by treatment with monoclonal anti-TGF-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97:8015–8020

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

Q1. Please check corresponding author if captured and presented correctly.
Q2. Figures 1,3 & 5 contains poor quality text. Please provide replacement. Otherwise, please advise if okay to proceed with the figure/s as is.
Q3. “Green et al. 2006” is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
Q4. Please advise if the captured abbreviated journal title is correct.